Health Discovery Corp (HDVY)

[bobafett]

HDVY (.0895) DD Alert POST- Diagnostic, Medical, Biotech, & Intellectual Property Company

Major Partnerships w/ Pfizer (NYSE), Abbott (NYSE), Quest Diagnostics (NYSE), CLRT (NASD), IART (NASD), BRKR (NASD) . These FORTUNE 500 companies have to pay royalty fees forever to these HDVY since HDVY licenses their SVM-RFE Technology to them and this company is not even $1.00. VRLMQ went from .06 to almost $20/share on the approval of the OVA (Ovarian Test) using the technology licensed to them by HDVY. Demonstrates how undervalued HDVY is at .38.

HDC’s License Partners (From 10/19/09 PR)

HDC’s key license partners to date include Abbott Laboratories (NYSE: ABT - News), Quest Diagnostics (NYSE: DGX - News), Clarient Inc. (Nasdaq: CLRT - News) and Pfizer Inc. (NYSE: PFE - News).
HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test with Quest Diagnostics Incorporated and Abbott Laboratories for development and commercialization. These licenses are solely for the use of HDC’s prostate cancer biomarkers in urine.
HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories and Clarient Inc. for development and commercialization. This license is solely for the use of HDC’s prostate cancer biomarkers in tissue biopsy specimens.
HDC has also partnered with Pfizer Inc. for use of HDC’s SVM and SVM-RFE pattern recognition technology in Pfizer’s global research and development.
HDC has also entered into a license with Smart Personalized Medicine, LLC (“SPM”), a privately-held company, founded by Dr. Richard Caruso, Chairman and founder of Integra Life Sciences (NasdaqGS: IART - News) to develop a superior breast cancer prognostic test using HDC’s SVM technology in cooperation with MD Anderson Cancer Center. HDC has a fifteen percent equity position in SPM and HDC will receive royalties from this new breast cancer prognostic test.
HDC has entered into a development and license agreement with DCL Medical Laboratories, LLC, for the collaborative development and commercialization of SVM-based computer assisted diagnostic tests for the independent detection of ovarian, cervical and endometrial cancers.
HDC’s Patents Cover Non-Medical Applications
There are a large number of non-medical applications protected by HDC’s patents, including but not limited to, fraud detection, investment and commodities price predictions, bankruptcy prediction, image and object analysis, face recognition, text and document classification, speech recognition, personalized consumer purchasing patterns, decryption, vehicle control and monitoring, weather forecasting and database marketing.
Total Number of Patents Pending and Issued
With the issuance of the new patents described above, HDC now holds exclusive rights to a total of 37 issued U.S. and foreign patents. There will be 41 when the 4 new ones (subjects of the Notices of Allowance) issue in the next few months. HDC has a total of 71 patents pending and issued. Importantly, the first expiration of any of the HDC patents is May 2019 and new patents are currently being filed which when granted will have an additional 20 years of protection for the Company.
HDC’s Successful Prosecution of Patent Infringement Cases
In addition to the Vermillion patent infringement case described above, HDC successfully prosecuted a patent infringement lawsuit against Equbits LLC, which resulted in a permanent injunction against Equbits, LLC.
“HDC is determined to continue to grow and protect its valuable intellectual property portfolio. The Equbits judgment and Vermillion settlement and limited license strengthens our licensing posture in the marketplace and sets the appropriate tone for our future enforcement efforts,” stated Stephen D. Barnhill, M.D., HDC’s Chairman and CEO.
“HDC remains firmly committed to successfully monetizing our valuable intellectual property through additional licensing, close collaboration, development and commercialization with our business partners and we will also continue to protect our patent portfolio through robust enforcement action when strategically appropriate," said Dr. Barnhill.
HDC’s patent strategy includes a significant after-claiming component with multiple CIP’s and Continuations already in place.




HDC has the only issued patents in the world for the SVM-RFE technology, which was discovered by members of the HDC science team. The SVM-RFE technology was the method used to discover the Company’s new tissue and urine based prostate cancer tests recently licensed to Quest Diagnostics (NYSE: DGX - News), Abbott Laboratories (NYSE: ABT - News) and Clarient Inc. (Nasdaq: CLRT - News).

Home Page


Home Page #2


Health Discovery Corporation’s Dr. Stephen Barnhill Tells Participants at London Conference That Biomarkers Patented by His Company Promise to Revolutionize The Field of Molecular Diagnostics
(Savannah, Ga.) September 24, 2009. Dr. Stephen Barnhill, Chairman and CEO, Health Discovery Corporation (OTCBB: HDVY) (“HDC”), a molecular diagnostics company, spoke at the “Biomarkers in Clinical Trials” Conference taking place in London, September 23-24, 2009. The conference is sponsored by The SMi Group, a London-based business-to-business conference group.
“Biomarkers promise to sharply accelerate the speed and accuracy of the drug discovery process and the efficacy of diagnostic testing,” said Dr. Barnhill. “Genetic biomarkers are at the heart of the new prostate cancer tests we have licensed to Quest Diagnostics and Abbott Laboratories. Combined with our sophisticated analysis tools for identifying positive results from massive amounts of previously unusable clinical data, biomarkers like those patented by HDC promise to revolutionize the field of molecular diagnostics.”
HDC has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics Incorporated (NYSE: DGX). HDC has also entered into an agreement with Abbott Laboratories (NYSE: ABT) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer.
Dr. Barnhill was joined on the conference faculty by representatives of Pfizer, Novartis Institutes for BioMedical Research, Astrazeneca, Merck Serono, MD Anderson Cancer Center and GlaxoSmithKline, among others.

Scientific Management Team


Kary B. Mullis won the Nobel Prize in Chemistry in 1993
Kary Mullis Ph.D. is a Biochemist who got the 1993 Nobel prize for his invention of the Polymerase Chain Reaction, a technique used in AIDS tests
http://www.virusmyth.com/aids/index/kmullis.htm

A Nobel Prize researcher is with Health Discovery. Dr. Mullis sees the potential!

Former Deputy FDA Commissioner John Norris Appointed Chief OperatingOfficer at Health Discovery Corporation.
http://www.allbusiness.com/medicine-health/diagnostics-screening-testing/13114880-1.html
Health Discovery Corporation (OTCBB:HDVY), a personalized medicinecompany specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathologyand radiology, announced that former Deputy FDA Commissioner John A.Norris has been appointed as Chief Operating Officer (COO) of the Company. He will be responsible for business development, primarily creating new strategic partnerships, licenses and contracts to complement the Company's existing agreements with Quest Diagnostics, Abbott Molecular, Pfizer, Bruker and Clarient (see also Health Discovery Corporation ).
"We are extremely fortunate to have attracted someone of John Norris' caliber," said Stephen D. Barnhill, M.D., chairman and CEO of Health Discovery Corporation (HDC). "We expect that his extensive experience and vast relationships in the healthcare space will make a very meaningful contribution to our growth trajectory. John is a visionaryleader who understands how the groundbreaking analytics that we havedeveloped and patented could change the face of diagnostic testing for personalized medicine. His extensive knowledge of the business of healthcare around the world will help us accelerate the commercialization of HDC's new gene-based urine test for prostate cancer."
According to Mr. Norris, "Dr. Barnhill has assembled a world-classteam of researchers, investigators and advisors who have pioneered abold new approach to diagnostics that will vastly improve the speed and accuracy of testing in the realm of gene-based testing, as well as in digital pathology and digital radiology." HDC holds 72 critical patents that are central to the digital convergence of diagnostics, pathology and radiology. "I am very pleased to be part of this outstanding team," Mr. Norris added.
"Our patented Support Vector Machine and Recursive Feature Elimination pattern recognition technologies have been independently validated by top researchers, academics and business professionals around the world and published in dozens of peer-reviewed medical and scientific journals and have broad applicability wherever highly accurate conclusions must be drawn from vast amounts of complex data," Dr. Barnhill said.
Dr. Barnhill continued, "In addition, we expect that John will be a huge asset in promoting our gene-based test for clinically significant prostate cancer recently licensed for commercialization to Abbott, Quest Diagnostics, and Clarient. Right now, half a million men a year in the United States alone have painful, expensive but unnecessarybiopsies for prostate cancer based solely on PSA findings, the current world standard for prostate cancer screening. The previously-announced results of our forthcoming urine-based test for prostate cancer could eliminate many of these unnecessary biopsies and unnecessary treatments such as radical prostate surgery stemming from false positive readings on the PSA test."


PATENTS
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,944,602.PN.&OS=PN/6,944,602&RS=PN/6,944,602

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=health+discovery&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PTXT


Prostate Cancer Quotes




Insight DX Test



http://www.urotoday.com/index.php?option=com_uij&view=single&issnum=8&volnum=2§ionid=27&Itemid=3369


Urology 1




Leukemia Test


BPH Test


CRC Test


AIDS Test




Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio

• Press Release
• Source: Health Discovery Corporation
• On 9:15 am EDT, Monday October 19, 2009
SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News) is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.
New U.S. and Foreign Patents
The United States Patent and Trademark Office (USPTO) issued a patent to HDC that includes additional, broader claims to the Company’s exclusive Recursive Feature Elimination (RFE) using Support Vector Machines (“SVM”) or SVM-RFE method, the first patent for which issued in 2006. The SVM-RFE method has been used to successfully identify the most important pieces of information needed to solve complex pattern-recognition problems and has been shown in numerous peer-reviewed publications from some of the worlds top academic institutions to be a superior technology for the successful discovery of new molecular diagnostic/prognostic tests for personalized medicine. HDC has the only issued patents in the world for the SVM-RFE technology, which was discovered by members of the HDC science team. The SVM-RFE technology was the method used to discover the Company’s new tissue and urine based prostate cancer tests recently licensed to Quest Diagnostics (NYSE: DGX - News), Abbott Laboratories (NYSE: ABT - News) and Clarient Inc. (Nasdaq: CLRT - News).
The European Patent Office issued a notice of its intent to grant a patent covering HDC’s SVM-based computer-aided image analysis techniques. Corresponding patents have already been granted in the U.S., Australia and Japan. This is an important patent for the successful development of SVM based digital pathology and radiology interpretations. This significant patent protects HDC’s development of new tests for cervical cancer (PAP Smear Interpretation), circulating tumor cell (CTC) analysis in breast cancer and radiologic interpretation of mammograms for breast cancer.
Another newly issued USPTO patent covers an SVM-based data-mining platform for classification of data from heterogeneous biological datasets.
The USPTO also issued a new patent to HDC covering a data-mining platform with multiple SVM modules for use in analyzing bioinformatics data.
In addition, the USPTO issued a new patent to HDC, which covers the use of SVM technology for ranking of input features for selection of the most relevant input parameters needed to classify data.
HDC was also issued a patent in Japan, which covers (RFE) using Support Vector Machines (“SVM”) for selection and ranking of the most important features within large datasets. This patent further protects HDC’s SVM-RFE technology outside the United States expanding our global protection of this very important discovery method for molecular diagnostic/prognostic test development for personalized medicine.
An Indian patent was issued to HDC covering the use of SVMs for knowledge discovery from multiple data sets. This patent further expands HDC’s patents for integrating patient data from multiple sources such as genomic data, clinical data, digital pathology data and radiologic data. This integration of data is thought to be the “Holy Grail” of personalized medicine.
A New FDA-Approved Ovarian Cancer Test based on an HDC Patented Technology
HDC’s patented technology played a pivotal role in identifying biomarkers in a recently FDA-approved ovarian cancer test developed by Vermillion, Inc. (VRMLQ.PK).
HDC prosecuted a patent infringement action against Vermillion’s predecessor company, Ciphergen Biosystems, Inc., which resulted in a $600,000 cash settlement in favor of HDC and a grant of a limited license to Vermillion by HDC. The HDC limited license grant to Vermillion is for non-exclusive use solely for Vermillion’s SELDI-based mass spectrometer technology.
HDC’s License Partners
HDC’s key license partners to date include Abbott Laboratories (NYSE: ABT - News), Quest Diagnostics (NYSE: DGX - News), Clarient Inc. (Nasdaq: CLRT - News) and Pfizer Inc. (NYSE: PFE - News).
HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test with Quest Diagnostics Incorporated and Abbott Laboratories for development and commercialization. These licenses are solely for the use of HDC’s prostate cancer biomarkers in urine.
HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories and Clarient Inc. for development and commercialization. This license is solely for the use of HDC’s prostate cancer biomarkers in tissue biopsy specimens.
HDC has also partnered with Pfizer Inc. for use of HDC’s SVM and SVM-RFE pattern recognition technology in Pfizer’s global research and development.
HDC has also entered into a license with Smart Personalized Medicine, LLC (“SPM”), a privately-held company, founded by Dr. Richard Caruso, Chairman and founder of Integra Life Sciences (NasdaqGS: IART - News) to develop a superior breast cancer prognostic test using HDC’s SVM technology in cooperation with MD Anderson Cancer Center. HDC has a fifteen percent equity position in SPM and HDC will receive royalties from this new breast cancer prognostic test.
HDC has entered into a development and license agreement with DCL Medical Laboratories, LLC, for the collaborative development and commercialization of SVM-based computer assisted diagnostic tests for the independent detection of ovarian, cervical and endometrial cancers.
HDC’s Patents Cover Non-Medical Applications
There are a large number of non-medical applications protected by HDC’s patents, including but not limited to, fraud detection, investment and commodities price predictions, bankruptcy prediction, image and object analysis, face recognition, text and document classification, speech recognition, personalized consumer purchasing patterns, decryption, vehicle control and monitoring, weather forecasting and database marketing.
Total Number of Patents Pending and Issued
With the issuance of the new patents described above, HDC now holds exclusive rights to a total of 37 issued U.S. and foreign patents. There will be 41 when the 4 new ones (subjects of the Notices of Allowance) issue in the next few months. HDC has a total of 71 patents pending and issued. Importantly, the first expiration of any of the HDC patents is May 2019 and new patents are currently being filed which when granted will have an additional 20 years of protection for the Company.
HDC’s Successful Prosecution of Patent Infringement Cases
In addition to the Vermillion patent infringement case described above, HDC successfully prosecuted a patent infringement lawsuit against Equbits LLC, which resulted in a permanent injunction against Equbits, LLC.
“HDC is determined to continue to grow and protect its valuable intellectual property portfolio. The Equbits judgment and Vermillion settlement and limited license strengthens our licensing posture in the marketplace and sets the appropriate tone for our future enforcement efforts,” stated Stephen D. Barnhill, M.D., HDC’s Chairman and CEO.
“HDC remains firmly committed to successfully monetizing our valuable intellectual property through additional licensing, close collaboration, development and commercialization with our business partners and we will also continue to protect our patent portfolio through robust enforcement action when strategically appropriate," said Dr. Barnhill.
HDC’s patent strategy includes a significant after-claiming component with multiple CIP’s and Continuations already in place.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscovercorp.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Contact:
Health Discovery Corporation
Media Relations:
Matthew Swetonic, 212-922-0900
[e-mail]
or
Investor Relations:
Tom Gallagher, 212-922-0900
[e-mail]